Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Accreditation Certification ISQua EEA

 
The Ministry of Public Health (MOPH) is proud to announce the reception of the prestigious Award by the International Society for Quality in Health Care – External Evaluation Association (ISQua EEA) for the Accreditation Standards of Hospitals in Lebanon 2022 Edition.

This development marks a crucial step forward for quality improvement and the enhancement of patient safety culture with internationally recognized standards.

Given the principal importance of improving healthcare management, quality of care, and patient safety in our hospitals, especially in these challenging times in Lebanon, we are committed to maintaining the accreditation process as an integral part of continuous healthcare improvement in Lebanon, with teams/trainers dedicated to improving care in hospitals, 44 trained surveyors and more than 500 health professionals from all hospitals in Lebanon currently being trained.

Special recognition goes to Dr. Walid Ammar for his leadership and guidance in transforming the hospital accreditation system in Lebanon.

We would like to extend our gratitude to Dr. Fadi El-Jardali and his team for their exceptional work in revising and improving the accreditation standards and tools. We also thank Dr. Ali Elhaj for his contributions during the initial phase of standards revision.

We are deeply grateful the financial support of AFD, to the Haute Autorité de Santé (HAS France) and all individuals who offered their advice and technical support, especially Dr. Bruno Lucet for his complete support during all the preparation process for the ISQua EEA certification.

We express our sincere appreciation to the Comité Technique d’Accréditation Hospitalière (CTAH) for their valuable feedback and suggestions, as well as the National Hospital Accreditation Committee (CNAH) including the main stakeholders: Ecole Supérieure des Affaires (ESA), Syndicate of Hospitals, Order of Physicians, Order of Nurses, Order of Pharmacists, Order of Midwives, Lebanese National Committee of Blood Transfusion, Army Medical Services, NSSF, MFE, and various faculties of medicine. We would like to acknowledge their contributions and their unwavering support.

Additionally, we extend our warm thanks to the national experts for their invaluable feedback and suggestions on the standards.

A special thanks to Perrine Malaud Wakim and the team of Pôle Santé at for their continuous dedication and support.

#Healthcare #Quality #Accreditation #Standards # Patient Safety Culture #MOPH #ESA #AFD #HAS #CNAH #CTAH #
    ...
    60
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AB02 REMICADE BioTech Infliximab - 100mg 100mg Injectable concentrated powder for solution 30,111,023 L.L
B02BX06 HEMLIBRA BioTech Emicizumab - 30mg/ml 30mg/ml Injectable solution L.L
A10AE01 HUMULIN N U-100 BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 701,486 L.L
L01FA01 ZYTUX BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 27,724,196 L.L
L04AB02 REMSIMA BioTech Infliximab - 100mg 100mg Injectable concentrated powder for solution 24,943,134 L.L
A10AE01 INSULATARD BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 752,552 L.L
L01FA03 GAZYVA BioTech Obinutuzumab - 1000mg/40ml 1000mg/40ml Injectable concentrate for solution 314,437,416 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 91,457,321 L.L
A10AE01 INSULATARD BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 752,552 L.L
D11AH05 DUPIXENT BioTech Dupilumab - 300mg 300mg Injectable solution 123,001,362 L.L
L01FB01 BESPONSA FOR INJECTION BioTech Inotuzumab Ozogamicin - 0.9mg 0.9mg Injectable powder for suspension 921,176,511 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 179,063,666 L.L
A10AE01 JUSLINE N BioTech Insulin human isophane - 100IU/ml 100IU/ml Injectable suspension 401,809 L.L
D11AH05 DUPIXENT BioTech Dupilumab - 300mg 300mg Injectable solution 123,001,362 L.L
L01FC01 DARZALEX BioTech Daratumumab - 400mg/20ml 400mg/20ml Injectable concentrate for solution 164,970,376 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 52,597,003 L.L
A10AE04 BASAGLAR KWIKPEN BioTech Insulin glargine - 100U/ml 100U/ml Injectable solution 4,114,846 L.L
D11AH05 DUPIXENT BioTech Dupilumab - 200mg 200mg Injectable solution 123,001,362 L.L
L01FC01 DARZALEX BioTech Daratumumab - 1800mg 1800mg Injectable solution 494,909,963 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 179,063,666 L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution L.L
A10AE04 GLARTUS BioTech Insulin glargine - 100U/ml 100U/ml Injectable solution 1,346,530 L.L
D11AH05 DUPIXENT BioTech Dupilumab - 200mg 200mg Injectable solution 123,001,362 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution + solvent 34,948,930 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 91,457,321 L.L
A10AE04 LANTUS SOLOSTAR BioTech Insulin glargine - 100IU/ml 100IU/ml Injectable solution 4,992,375 L.L
B03XA01 BINOCRIT BioTech Erythropoietin recombinant human (Epoetin alfa) - 2,000IU/ml 2,000IU/ml Injectable solution 6,544,700 L.L
L01FD01 HERCEPTIN BioTech Trastuzumab - 440mg 21mg/ml Injectable concentrated powder for solution+diluent 166,423,476 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 52,597,003 L.L
A10AE04 LANTUS BioTech Insulin glargine - 100IU/ml 100IU/ml Injectable solution 3,327,354 L.L
    ...
    60
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025